

# WIKINGO Project Systematic Analysis

## Tables & Figures.

Proyecto Vikingo

September 29, 2016

`proyectovikingo@proyectovikingo.es`

## Contents

### List of Tables

1	Participant characteristics . . . . .	3
2	According to Local Recurrence . . . . .	4
3	According to Metastasis . . . . .	6
4	According to Exitus . . . . .	8
5	Incidence by outcome [95% CI] . . . . .	13

### List of Figures

1	Local Recurrence . . . . .	5
2	Metastasis . . . . .	7
3	Exitus . . . . .	9
4	Local Recurrence, according to Type of Resection: . . . . .	10
5	Metastasis, according to Type of Resection: . . . . .	11
6	Survival, according to Type of Resection: . . . . .	12

Table 1: Participant characteristics

	[ALL] N=216	N
Age	67.1 (11.5)	216
Sex: Men	134 (62.0%)	216
Tumor level:		216
0-6cm	83 (38.4%)	
7-12cm	91 (42.1%)	
13-15cm	42 (19.4%)	
Tumor stage:		216
0	14 (6.48%)	
I	67 (31.0%)	
II	54 (25.0%)	
III	81 (37.5%)	
Neoadjuvant treatment	81 (37.5%)	216
Type of resection:		216
Abdominoperineal resection	56 (25.9%)	
Anterior resection	142 (65.7%)	
Hartmann	18 (8.33%)	
Perforation	16 (7.41%)	216
Invasion circumferential margin	27 (12.5%)	216
Mesorecto quality:		211
Satisfactory	174 (82.5%)	
Partial	30 (14.2%)	
No-satisfactory	7 (3.32%)	
Recidive	7 (3.24%)	216
Months to recidive	29.0 [12.0;51.0]	216
Metastasis	45 (20.8%)	216
Months to Metastasis	24.5 [10.0;48.2]	216
Exitus	53 (24.5%)	216
Months to exitus	29.0 [13.0;51.2]	216


Table 2: According to Local Recurrence

	No event n= 209	Event n= 7	Crude HR	p-value	Multivariate HR	p-value
Age (10y)	6.71 (1.15)	6.57 (1.12)	0.94 [0.48;1.84]	0.849	0.58 [0.24; 1.40]	0.225
Sex: Men	130 (62.2%)	4 (57.1%)	0.83 [0.19;3.71]	0.809	0.39 [0.05; 2.78]	0.346
Tumor level:						
0-6cm	79 (37.8%)	4 (57.1%)	2.08 [0.23;18.6]	0.514	101364903.04 [0.00; Inf]	0.999
7-12cm	89 (42.6%)	2 (28.6%)	0.86 [0.08;9.49]	0.901	64355377.22 [0.00; Inf]	0.999
Tumor stage:						
0	14 (6.70%)	0 (0.00%)	1.00 [0.00;.]	1.000	0.53 [0.00; Inf]	1
II	52 (24.9%)	2 (28.6%)	273386899 [0.00;.]	0.999	85224510.38 [0.00; Inf]	0.998
III	76 (36.4%)	5 (71.4%)	605503917 [0.00;.]	0.999	136408036.85 [0.00; Inf]	0.998
Neoadjuvant treatment	77 (36.8%)	4 (57.1%)	1.81 [0.40;8.17]	0.439	1.97 [0.24; 16.29]	0.531
Type of resection:						
Abdominoperineal resection	53 (25.4%)	3 (42.9%)	3.10 [0.63;15.4]	0.166	1.39 [0.07; 25.97]	0.827
Hartmann	17 (8.13%)	1 (14.3%)	3.87 [0.40;37.3]	0.242	10.42 [0.58;187.43]	0.112
Perforation	14 (6.70%)	2 (28.6%)	5.78 [1.12;29.9]	0.036	2.52 [0.22; 29.26]	0.459
Invasion circumferential margin	24 (11.5%)	3 (42.9%)	6.04 [1.35;27.1]	0.019	2.74 [0.36; 20.86]	0.332
Mesorecto quality:						
Partial	29 (14.1%)	1 (16.7%)	1.64 [0.18;14.7]	0.659	1.09 [0.10; 11.55]	0.94
No-satisfactory	6 (2.93%)	1 (16.7%)	15.1 [1.56;146]	0.019	8.13 [0.13;499.57]	0.319

Reference categories:

- Age, a decade
- Sex, Women
- Tumor level, 13-15cm
- Tumor stage: 1
- Neoadjuvant treatment, No
- Type of resection, Anterior resection
- Perforation, No
- Invasion circumferential margin, No
- Mesorecto Quality, Satisfactory

Figure 1: Local Recurrence



Months	0	12	24	36	48	60
N:	216	161	118	83	60	45


Table 3: According to Metastasis

	No event n= 171	Event n= 45	Crude HR	p-value	Multivariate HR	p-value	N
Age (10y)	6.69 (1.17)	6.77 (1.08)	1.15 [0.87;1.53]	0.328	0.98 [0.73; 1.33]	0.91	216
Sex: Men	105 (61.4%)	29 (64.4%)	1.13 [0.61;2.08]	0.701	1.23 [0.63; 2.39]	0.541	216
Tumor level:							216
0-6cm	64 (37.4%)	19 (42.2%)	1.04 [0.47;2.30]	0.922	0.37 [0.11; 1.25]	0.11	
7-12cm	74 (43.3%)	17 (37.8%)	0.78 [0.35;1.76]	0.554	0.49 [0.18; 1.32]	0.159	
Tumor stage:							216
0	12 (7.02%)	2 (4.44%)	1.53 [0.30;7.91]	0.609	2.29 [0.39;13.51]	0.359	
II	43 (25.1%)	11 (24.4%)	2.15 [0.74;6.18]	0.157	2.08 [0.64; 6.74]	0.223	
III	54 (31.6%)	27 (60.0%)	5.33 [2.05;13.9]	0.001	4.87 [1.63;14.59]	0.005	
Neoadjuvant treatment	63 (36.8%)	18 (40.0%)	0.83 [0.45;1.51]	0.537	1.08 [0.50; 2.31]	0.851	216
Type of resection:							216
Abdominoperineal resection	41 (24.0%)	15 (33.3%)	2.01 [1.05;3.84]	0.034	2.89 [1.06; 7.91]	0.038	
Hartmann	12 (7.02%)	6 (13.3%)	3.89 [1.57;9.60]	0.003	5.23 [1.73;15.81]	0.003	
Perforation	13 (7.60%)	3 (6.67%)	0.95 [0.29;3.06]	0.929	0.48 [0.11; 2.09]	0.329	216
Invasion circumferential margin	17 (9.94%)	10 (22.2%)	2.12 [1.05;4.29]	0.036	2.33 [0.99; 5.49]	0.054	216
Mesorecto quality:							211
Partial	20 (11.8%)	10 (23.8%)	2.32 [1.13;4.74]	0.022	1.79 [0.83; 3.86]	0.136	
No-satisfactory	6 (3.55%)	1 (2.38%)	1.96 [0.27;14.5]	0.509	1.21 [0.11;13.63]	0.877	

Reference categories:

- Age, a decade
- Sex, Women
- Tumor level, 13-15cm
- Tumor stage: 1
- Neoadjuvant treatment, No
- Type of resection, Anterior resection
- Perforation, No
- Invasion circumferential margin, No
- Mesorecto Quality, Satisfactory

Figure 2: Metastasis



Months	0	12	24	36	48	60
N:	216	151	108	76	54	39

Table 4: According to Exitus


	No event n= 163	Event n= 53	Crude HR	p-value	Multivariate HR	p-value	N
Age (10y)	6.55 (1.14)	7.20 (1.02)	1.71 [1.30;2.25]	<0.001	1.18 [0.87; 1.59]	0.289	216
Sex: Men	98 (60.1%)	36 (67.9%)	1.32 [0.74;2.35]	0.346	1.20 [0.66; 2.20]	0.55	216
Tumor level:							216
0-6cm	54 (33.1%)	29 (54.7%)	1.82 [0.83;3.98]	0.134	0.89 [0.29; 2.77]	0.844	
7-12cm	75 (46.0%)	16 (30.2%)	0.83 [0.35;1.94]	0.666	0.72 [0.26; 1.96]	0.516	
Tumor stage:							216
0	14 (8.59%)	0 (0.00%)	0.00 [0.00;.]	0.995	0.00 [0.00; Inf]	0.996	
II	44 (27.0%)	10 (18.9%)	0.72 [0.32;1.65]	0.443	0.47 [0.19; 1.13]	0.093	
III	51 (31.3%)	30 (56.6%)	1.93 [1.01;3.71]	0.048	1.22 [0.59; 2.53]	0.586	
Neoadjuvant treatment	68 (41.7%)	13 (24.5%)	0.42 [0.23;0.79]	0.007	0.40 [0.18; 0.89]	0.025	216
Type of resection:							216
Abdominoperineal resection	31 (19.0%)	25 (47.2%)	4.00 [2.20;7.27]	<0.001	3.85 [1.62; 9.15]	0.002	
Hartmann	9 (5.52%)	9 (17.0%)	5.57 [2.51;12.3]	<0.001	4.77 [1.83;12.45]	0.001	
Perforation	10 (6.13%)	6 (11.3%)	1.80 [0.77;4.22]	0.174	0.85 [0.28; 2.55]	0.769	216
Invasion circumferential margin	13 (7.98%)	14 (26.4%)	2.61 [1.41;4.81]	0.002	2.20 [1.04; 4.66]	0.039	216
Mesorecto quality:							211
Partial	21 (13.1%)	9 (17.6%)	1.54 [0.75;3.20]	0.242	2.09 [0.94; 4.63]	0.071	
No-satisfactory	3 (1.88%)	4 (7.84%)	5.17 [1.82;14.7]	0.002	2.85 [0.69;11.83]	0.15	

Reference categories:

- Age, a decade
- Sex, Women
- Tumor level, 13-15cm
- Tumor stage: 1
- Neoadjuvant treatment, No
- Type of resection, Anterior resection
- Perforation, No
- Invasion circumferential margin, No
- Mesorecto Quality, Satisfactory




Figure 3: Exitus




Months	0	12	24	36	48	60
N:	216	164	121	84	62	46

Figure 4: Local Recurrence, according to Type of Resection:




Tiempo	0	12	24	36	48	60
Abd	56	37	27	19	12	9
Ant	142	119	90	65	47	36
H	18	9	5	5	2	0

Figure 5: Metastasis, according to Type of Resection:



Tiempo	0	12	24	36	48	60
Abd	56	36	25	15	11	8
Ant	142	112	82	59	42	31
H	18	6	4	4	2	0

Figure 6: Survival, according to Type of Resection:



Tiempo	0	12	24	36	48	60
Abd	56	39	29	19	12	9
Ant	142	119	90	66	49	37
H	18	10	6	5	2	0

Table 5: Incidence by outcome [95% CI]

Months	Local Recurrence	Metastasis	Exitus
12	2.1 [4.12; 0.04]	8.13 [11.89; 4.22]	10.84 [15.03; 6.44]
24	2.75 [5.12; 0.33]	16.5 [22.03; 10.58]	19.37 [24.94; 13.39]
36	3.78 [6.83; 0.63]	24.74 [31.51; 17.31]	30.6 [37.5; 22.95]
48	4.97 [8.73; 1.05]	27.88 [35.12; 19.83]	31.48 [38.47; 23.7]
60	4.97 [8.73; 1.05]	34.18 [42.7; 24.38]	32.75 [39.97; 24.66]